{
  "source": "PA-Notification-Osphena.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1277-7\nProgram Prior Authorization/Notification\nMedication Osphena® (ospemifene)\nP&T Approval Date 3/2019, 3/2020, 3/2021, 3/2022, 3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nOsphena (ospemifene) is indicated for the treatment of moderate to severe dyspareunia, a\nsymptom of vulvar and vaginal atrophy due to menopause and for the treatment of moderate to\nsevere vaginal dryness, a symptom of vulvar and vaginal atrophy (VVA) due to menopause.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Benefit designs covering medications to treat sexual dysfunction\na. Osphena will be approved based on the following criteria:\n(1) Diagnosis of one of the following:\n(a) Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal\natrophy due to menopause\n(b) Treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal\natrophy (VVA) due to menopause.\n2. Benefit designs excluding medications to treat sexual dysfunction\na. Osphena will be approved based on the following criterion:\n(1) Treatment of moderate to severe vaginal dryness, a symptom of VVA due to menopause\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Osphena will be approved based on the following criterion:\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit plan\ncoverage may also impact coverage criteria. Other policies and utilization management programs may\napply.\n© 2025 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Supply limits may be in place\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or the",
    "al and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Osphena [package insert]. Princeton, NJ: Duchesnay USA, Inc; February 2024.\nProgram Prior Authorization/Notification - Osphena\nChange Control\nDate Change\n3/2019 New program\n3/2020 Annual review. Updated references.\n3/2021 Annual review. No changes.\n3/2022 Annual review. No changes.\n3/2023 Annual review. Added mandate language.\n3/2024 Annual review. Updated references.\n3/2025 Annual review. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}